Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116181 · ClinicalTrials.gov registry record · Phase 3
Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis
A Phase 3 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00116181 is a Phase 3 study that has completed, run by Rockefeller University. The registered enrollment target is 30 participants.
The verdict
NCT00116181, a Phase 3 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The investigator's laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Etanercept, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris. This trial is a phase III study to help understand the action of the drug etanercept, trade name Enbrel, for the adult patient with moderate to severe plaque psoriasis and who is a candidate for internal medications.
Interventions
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116181
The ClinicalTrials.gov registry entry for NCT00116181 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT00116181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116181 about?
NCT00116181 is a clinical study titled "Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis". The investigator's laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Etanercept, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The el...
What is the current status of trial NCT00116181?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00116181?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00116181?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.